Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions

Completed · Phase 1

Conditions studied: Healthy

In brief

The objective of this single-dose, open-label, randomized, two-period crossover study was to compare the rate of absorption and oral bioavailability of a test formulation of doxycycline monohydrate 1 x 25 mg (5mL) oral suspension manufactured by IVAX Pharmaceuticals, Inc. and distributed by TEVA Pharmaceuticals USA to an equivalent oral dose of the commercially available reference product, Vibramycin Monohydrate® manufactured by Pfizer, Inc. following an overnight fast of at least 10 hours.

Key facts

Study ID
NCT00829764
Run by
Teva Pharmaceuticals USA
People needed
30
Starts
2006-10-01
Expected to finish
2006-10-01
Last updated by the study team
2024-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.